XBiotech Inc. (NASDAQ:XBIT) traded up 4.7% on Wednesday . The stock traded as high as $14.15 and last traded at $14.14, with a volume of 59,305 shares traded. The stock had previously closed at $13.51.

Several equities research analysts recently weighed in on the company. Noble Financial restated a “buy” rating and set a $24.00 target price on shares of XBiotech in a research note on Thursday, May 19th. Zacks Investment Research upgraded XBiotech from a “hold” rating to a “buy” rating and set a $15.00 target price for the company in a research note on Tuesday, May 24th.

The firm has a 50 day moving average of $16.41 and a 200-day moving average of $12.37. The firm’s market capitalization is $469.08 million.

In other news, Director W Thorpe Mckenzie acquired 20,000 shares of the business’s stock in a transaction dated Thursday, May 26th. The shares were bought at an average cost of $13.96 per share, for a total transaction of $279,200.00. Following the acquisition, the director now directly owns 3,898,600 shares in the company, valued at approximately $54,424,456. The purchase was disclosed in a filing with the SEC, which is available through this link.

XBiotech Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing True Human monoclonal antibodies for treating a range of diseases. The Company focuses on bringing its lead product candidate, Xilonix (MABp1), to market. The Company has also developed a True Human monoclonal antibody discovery platform and manufacturing system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.